DDX11 and hepatocellular carcinoma: To define the molecular mechanisms underlying the oncogenic activity of DDX11 in HCC, Yu and collaborators focused on the PI3K/AKT/mTOR pathway, based on the results of a bioinformatics analysis (gene set variation analysis, GSVA), indicating that genes of this pathway are altogether considerably enriched in HCC tissues displaying high DDX11 expression.